HOME >> BIOLOGY >> NEWS
JCI table of contents November, 2005

EDITOR'S PICK
A NOVEL MECHANISM OF ACTION FOR LEAD ANTI-TUMOR AGENT

Anti-angiogenic agents have been successful in the clinic for blocking the growth of solid tumors. However, these agents used in combination with chemotherapy have improved the survival of patients with cancers by only several months. Therefore, identification of unrecognized angiogenic pathways that selectively support tumor neo-vessel assembly will increase the efficacy of anti-angiogenic or anti-vascular therapy.

The prototypical vascular targeting agent combretastatin A4 phosphate (CA4P) exerts its anti-angiogenic effect by targeting unstable budding tumor neo-vessels. CA4P is currently being studied in clinical trials in oncology.

In a paper appearing online on October 6 in advance of print publication of the November issue of the Journal of Clinical Investigation, Shahin Rafii and colleagues from Cornell University provide important mechanistic data demonstrating how CA4P has anti-tumor and anti-angiogenic activity.

The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.

Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.

TITLE: Combretastatin A4 phosphate disrupts tumor vasculature and growth by interfering with vascular endothelial-cadherin
'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
6-Oct-2005


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... York, NY (PRWEB) , ... October 12, 2017 ... ... Academy of Sciences today announced the three Winners and six Finalists of the ... are given annually by the Blavatnik Family Foundation and administered by the New ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
Cached News: